<div id="readability-page-1">04:43 AM EST, 01/30/2026 (MT Newswires) -- AstraZeneca ( AZN ) said early Friday it will pay $1.2 billion to CSPC Pharmaceuticals to advance multiple therapies for obesity and type 2 diabetes across eight programs.CSPC is eligible to receive development and regulatory milestones of up to $3.5 billion across all programs, AstraZeneca ( AZN ) said. It will also be eligible for further commercialisation and sales milestones as well as tiered royalties.The companies will initially progress four programs, deploying CSPC's artificial intelligence-driven peptide drug discovery platform and its proprietary LiquidGel once-monthly dosing platform technology, according to the statement.As part of the deal, AstraZeneca ( AZN ) will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight-management portfolio, it said. The company also has option to pursue future metabolic programs, leveraging CSPC's dosing platform technology, and holds rights to deploy this across internal development programs.The transaction is expected to close in Q2. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

阿斯利康將支付 12 億美元給中科院藥業，以增強其體重管理產品組合，重點關注肥胖和 2 型糖尿病的治療。中科院藥業可能在開發和監管里程碑中獲得高達 35 億美元的收益。該交易包括中科院藥業每月一次注射的體重管理產品在中國以外的獨家全球權利，以及未來代謝項目的選擇權。預計交易將在第二季度完成

AstraZeneca to Pay $1.2 Billion Upfront to CSPC Pharmaceuticals to Expand Weight Management Portfolio

fidelity

標普生物技術 ETF - SPDR

阿斯利康

醫療業 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

基因改革 ETF - ARK

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

阿斯利康將向石藥集團支付 12 億美元的預付款，以擴展其體重管理產品組合